

Drug Utilization Review Board

(DUR Board)

Meeting – April 8, 2009 @ 6:00 p.m.

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. McNeill, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. March 11, 2009 DUR Minutes – Vote
 - B. March 26, 2009 DUR Recommendation Memorandum
 - C. Results of 2009 Supplemental Rebate Agreements

Items to be presented by Dr. Keast, Dr. McNeill, Chairman:

4. **Update on DUR / MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review for January 2009
 - B. Retrospective Drug Utilization Review Response for November 2008
 - C. Medication Coverage Activity Audit for March 2009
 - D. Help Desk Activity Audit for March 2009

Items to be presented by Dr. Robinson, Dr. McNeill, Chairman

5. **Action Item – Vote to Prior Authorize Zolpimist™ – See Appendix C.**
 - A. COP Recommendations
 - B. Current Hypnotics PA Criteria

Items to be presented by Dr. Le, Dr. McNeill, Chairman

6. **30 Day Notice to Prior Authorize Ryzolt™ – See Appendix D.**
 - A. Product Summary
 - B. Current Ultram® ER PA Criteria
 - C. COP Recommendations
 - D. Product Details

Items to be presented by Dr. Le, Dr. McNeill, Chairman

7. **30 Day Notice to Prior Authorize Aplenzin[®] – See Appendix E.**
 - A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

8. **30 Day Notice to Prior Authorize New Proton Pump Inhibitor Products – See Appendix F.**
 - A. Product Summaries
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Keast, Dr. McNeill, Chairman

9. **60 Day Notice to Prior Authorize Anti-Migraine Products and 30 Day Notice to Prior Authorize Treximet[®] – See Appendix G.**
 - A. Utilization Review
 - B. COP Recommendations

Items to be presented by Dr. Graham, Dr. McNeill, Chairman

10. **FDA and DEA Updates – See Appendix H.**

11. **Future Business**
 - A. Utilization Review of Fibromyalgia
 - B. Utilization Review of Otic Antibiotics
 - C. Utilization Review of Antiemetics
 - D. New Product Reviews

12. **Adjournment**